Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: A European perspective

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 6, 2013, Pages 639-651

  Colombo, Massimo ^a   Raoul, Jean Luc ^c   Lencioni, Riccardo ^b   Galle, Peter R ^e   Zucman Rossi, Jessica ^d   Bañares, Rafael ^g   Seehofer, Daniel ^f   Neuhaus, Peter ^f   Johnson, Philip ^h  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c INSTITUT PAOLI CALMETTES   (France)

^d INSERM   (France)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

brivanib; everolimus; hepatocellular carcinoma; linifanib; radiofrequency ablation; ramucirumab; sorafenib; transarterial chemoembolization; transplantation

Indexed keywords

AXITINIB; BEVACIZUMAB; BRIVANIB; C 1008; CABOZANTINIB; CISPLATIN; DOVITINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FRESOLIMUMAB; GOLVATINIB; LENALIDOMIDE; LINIFANIB; MAPATUMUMAB; NINTEDANIB; PLACEBO; RAMUCIRUMAB; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHEMOEMBOLIZATION; DIABETES MELLITUS; EARLY DIAGNOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; LIVER TRANSPLANTATION; OBESITY; PATIENT ATTITUDE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; HEPATECTOMY; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 84877121118     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835e33bb     Document Type: Review

References (102)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Ca Cancer J Clin 2011; 61:69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, cancer incidence, mortality and prevalence worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer 2010; Available at: http://globocan.iarc.fr/[Accessed 6 June 2012].
3. Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer 2012; 14:2125-2136.
4. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:1485-1491.
5. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; Available at: http://seer.cancer.gov/csr/1975- 2009-pops09/[Accessed 1 December 2012].
6. Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Coebergh JW, et al. The EUROCARE Working Group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8:773-783.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-1022, Available at: http://www.aasld.org/ practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010. pdf [Accessed 3 July 2012].
8. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943.
9. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130:417-422.
10. Trinchet J-C, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Groupe d'Etude et de Traitement du Carcinoma He patocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3-and 6-month periodicities. Hepatology 2011; 54:1987-1997.
11. Johnson P, Degos F, Colombo M, Sherman M, Huang B, Orsini L. Observations of hepatocellular carcinoma (HCC) management patterns from the multinational BRIDGE study-first overall analysis of the European cohort [abstract]. Eur J Cancer 2011; 47 (Suppl 1):6501.
12. Ikai I, Kudo M, Arii S, Omata M, Masamichi K, Sakamoto M, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010; 40:1043-1059.
13. Schirmacher P, Bedossa P, Roskams T, Tiniakos DG, Brunt EM, Zucman-Rossi J, et al. Fighting the bushfire in HCC trials. J Hepatol 2011; 55:276-277.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti AAJCC Cancer Staging Handbook. 7th ed. New York, NY: Springer; 2010.
15. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56:918-928.
16. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-338.
17. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28:751-755.
18. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94:1760-1769.
19. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38:207-215.
20. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome He patocellulaire. J Hepatol 1999; 31:133-141.
21. Forner A, Reig ME, Rodriguez de Lope C, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30:61-74.
22. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41:707-715.
23. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010; 28:2889-2895.
24. Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2012; 6:173-185.
25. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: hepatobiliary cancers, V 2.2012. Available at: www.nccn.org [Accessed 3 July 2012].
26. Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 2010; 12:139-146.
27. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for HCC: an evidence-based analysis on 15 years of experience. Liver Transpl 2011; 17 (Suppl 12):S44-S57.
28. Bozorgzadeh A, Orloff M, Abt P, Tsoulfas G, Younan D, Kashyap R, et al. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl 2007; 13:807-813.
29. Clavien P-A, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, et al. On behalf of the OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13:e11-e22.
30. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10:35-43.
31. Heckman JT, Devera MB, Marsh JW, Fontes P, Amesur NB, Holloway SE, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 2008; 15:3169-3177.
32. Frangakis C, Geschwind JF, Kim D, Chen Y, Koteish A, Hong K, et al. Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. Cardiovasc Intervent Radiol 2011; 34:1254-1261.
33. Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010; 51:1284-1290.
34. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati KL, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice. Hepatology 2008; 47:82-89.
35. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008; 43:727-735.
36. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228:235-240.
37. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210:655-661.
38. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol 2010; 52:380-388.
39. Bouza C, Lo pez-Cuadrado T, Alca zar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009; 9:31-40.
40. Ku nzli BM, Abitabile P, Maurer CA. Radiofrequency ablation of liver tumors: actual limitations and potential solutions in the future. World J Hepatol 2011; 3:8-14.
41. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012; 262:43-58.
42. Llovet JM, Bruix J. Barcelona-Cl?nic Liver Cancer Group. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442.
43. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37:212-220.
44. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. PRECISION V Investigators. Prospective randomized study of doxorubicineluting- bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41-52.
45. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103:914-921.
46. Lencioni R, Llovet JM, Han G, Tak W-Y, Yang J, Leberre M-A, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial [abstract]. J Clin Oncol 2012; 30 (Suppl 4):LBA154.
47. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138:52-64.
48. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47:71-81.
49. Hilgard P, Hamami M, Fouly AE, Scherag A, Mu ller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52:1741-1749.
50. Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66:792-800.
51. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in linger time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140:497-507.
52. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007; 141:330-339.
53. Shah SA, Wei AC, Cleary SP, Yang I, McGilvray ID, Gallinger S, et al. Prognosis and results after resection of very large (Z10 cm) hepatocellular carcinoma. J Gastrointest Surg 2007; 11:589-595.
54. Zhong J-H, Li H, Li L-Q, You X-M, Zhang Y, Zhao Y-N, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol 2012; 38: 286-295.
55. Chu KJ, Lai EC, Yao XP, Zhang HW, Lau WY, Fu XH, et al. Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation-a systematic review and meta-analysis. Asian J Surg 2010; 33:120-126.
56. Lau WY, Lai EC, Leung TW, Yu SCH. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-years and 10-years survival. Ann Surg 2008; 247:43-48.
57. Peng B-G, Liang L-J, He Q, Kaung M, Lia J-M, Lu M-D, Huang J-F. Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol 2005; 11:700-704.
58. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11:790-800.
59. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003; 2 (Suppl 1):S127-S133.
60. Semela D, Dufour J-F. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41:864-880.
61. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
62. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009; 10:25-34.
63. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 2010; 16:390-397.
64. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, et al. SOFIA (SOraFenib Italian Assessment) Study Group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54:2055-2063.
65. Cabibbo G, Latteri F, Antonucci M, Crax? A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 2009; 6:159-169.
66. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol 2012; 56:267-275.
67. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10:116-129.
68. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:6146-6153.
69. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002; 35:834-842.
70. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8:299-309.
71. Park J-W, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17:1973-1983.
72. Finn RS, Kang Y-K, Mulcahy M, Polite BN, Lim HY,Walters I, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18:2090-2098.
73. Llovet JM, Decaens T, Raoul J-L, Coucher E, Kudo M, Chang C, et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study [abstract]. J Hepatol 2012; 56 (Suppl 2):1398.
74. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10:794-800.
75. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 20:3027-3035.
76. Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010; 15:285-292.
77. Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin A, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol 2011; 29 (15S):4000.
78. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei R-Q, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006; 5:995-1006.
79. Toh H, Chen P, Carr BI, Knox JJ, Gill S, Qian J, et al. Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol 2010; 28 (15S):4038.
80. Zhu A, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz J, et al. A phase 2 study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC): updated results (CP12-0710/NCT00627042). Presented at ICLA Annual Conference; 10-12 September 2010; Montreal, QC [abstract O-033].
81. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27:55-76.
82. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011; 117:5094-5102.
83. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27:843-850.
84. Kaseb AO, Iwasak M, Javle M, Onicescu G, Garrett-Mayer E, Abbruzzese JL, et al. Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol 2009; 27 (15S):4522.
85. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib versus doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304:2154-2160.
86. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
87. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60.
88. Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118:147-156.
89. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation. J Hepatol 2011; 55:1309-1316.
90. Shim JH, Lee HC, Kim S-O, Shin YM, Kim KM, Lim Y-S, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262:708-718.
91. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711.
92. Garattini S, Bertele' V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 2007; 370:1875-1877.
93. Johnson PJ. Critical issues in the design and implementation of clinical trials in hepatocellular carcinoma. Expert Rev Anticancer Ther 2003; 3:421-423.
94. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44:694-698.
95. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 2010; 30:75-86.
96. Nault J-C, Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 2011; 31:173-187.
97. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991; 338:1356-1359.
98. Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, et al. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer 2012; 48:2328-2338.
99. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45:42-52.
100. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359:1995-2004.
101. Di Tommaso L, Destro A, Fabbris V, Spagnuolo G, Fracanzani AL, Fargion S, et al. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 2011; 53:1549-1557.
102. Nault JC, de Reynie s A, Couchy G, Tran Van Nhieu J, Decaens T, Laurent A, et al. A molecular signature and algorithm for the diagnosis and prognosis of hepatocellular tumors [abstract]. J Hepatol 2011; 54 (Suppl 1):76.